NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

August 18, 2026

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

The EU-Japan Biotech Business Mission focuses on business development and partnering between European and Japanese life science companies. The programme begins in September with digital business training, market intelligence and online partnering. The focus will be on activities in Japan 5–9 October, including the EU-Japan Biotech & Pharma Partnering Conference in Osaka and participation in BioJapan in Yokohama.

The selection follows NextCell’s participation in the first round of the Japan Entry Acceleration Program (JEAP), initiated and funded by the Japan External Trade Organization (JETRO). NextCell was one of only ten companies globally, and the only Swedish company, selected for the programme’s first cohort. Following the completion of JEAP, NextCell was encouraged by JETRO to apply for the EU-Japan Biotech Business Mission.

NextCell’s activities in Japan have provided the Company with access to industry and regulatory stakeholders and a deeper understanding of potential development pathways for NXTCL-T1D. Discussions with, among others, the PMDA, regulatory advisors and industry stakeholders have also provided greater clarity on potential models for future development and commercialisation, including the possibility of retaining manufacturing outside Japan.

In Hong Kong, NextCell has previously established the wholly owned subsidiary NextCell Hong Kong Limited as part of the Company’s strategy for Asia. NextCell is also a member of the Swedish Chamber of Commerce in Hong Kong and the Hong Kong Chamber of Commerce in Sweden. The office and membership in HSITP now represent a further step in strengthening the Company’s local presence.

“Over the past year, we have implemented our Asia strategy step by step. Our activities in Japan and Hong Kong have provided us with concrete regulatory and industry contacts, strengthened our network and clarified potential pathways for further development and commercialisation. The next step is to translate these efforts into partnerships for NXTCL in Asia,” says Mathias Svahn, CEO of NextCell.

For more information, please contact:
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com

Website:: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company’s lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hongkong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.

Download attachmentRead full press release on Cision (external link)
2018-03-14
Nordic Tech House to invest in stem cell company NextCell Pharma
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva. The two-year agreement means that Nordic Tech House will be responsible ...
Read moreRead more
2018-03-06
NextCell CEO invited speaker at the Swedish National ATMP Conference
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th. The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord. NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th. The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoi...
Read moreRead more
2018-02-22
Three patients now treated with NextCells ProTrans stem cells
NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment. The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can start inclusion of patients in the
NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment. The trial performed with NXCTCL's patent-pending ProTrans, is divided into t...
Read moreRead more
2018-02-16
NextCell Pharma files patent application
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorithm is based on multiple functional assays used to identify and select cells and donors with specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple donors. The pooling process supports the production of large batches. The combination
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorith...
Read moreRead more
2018-01-31
NextCell Pharma changes ticker to NXTCL
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications and company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will remain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation.
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in gener...
Read moreRead more
2018-01-24
First diabetes patient treated with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years. The clinical trial started on November 28th, 2017 and after clinical assessment and baseline data collection, the first patient has now been treated (first-in-human) with ProTrans stem cells. The first part of the study is a three-step dose escalation with three patients in each
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a max...
Read moreRead more
2017-11-29
NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production are candidates for participation in the trial. NextCell Pharma has reached a new level as a company. I would like to thank all the
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving Pr...
Read moreRead more
2017-11-14
Today Nextcell Pharma publishes its annual report 2016-2017
NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com
NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com...
Read moreRead more